Xeris Biopharma Holdings, Inc. (XERS)

Over the past six months, Xeris Biopharma Holdings, Inc. stock has experienced significant positive momentum. The share price saw an increase of 185.14% between October 28, 2024, and October 24, 2025. More recently, the stock delivered a 187.8% return over the last year, with a 166.2% rally year-to-date in 2024. A 12.6% jump was observed over the last month, though there was a slight dip of 0.3% in the week prior to October 26, 2025. Key events impacting the stock price include strong financial results and raised guidance, product pipeline and regulatory developments, an Analyst and Investor Day, and insider trading activities.

Information explicitly detailing demand seasonality for Xeris Biopharma Holdings, Inc.'s products and services is not readily available. While there is a mention of stock seasonality, this refers to stock performance rather than product demand. The company has reported "rapidly expanding patient demand" for Recorlev and Gvoke, driven by product differentiation, growing prevalence of related conditions, and increased awareness; however, these statements do not indicate any specific seasonal patterns in demand for their pharmaceutical products.

Xeris Biopharma Holdings, Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing ready-to-use therapeutic medicines for chronic endocrine and neurological diseases. The company utilizes its proprietary XeriSol and XeriJect technology platforms to enhance drug delivery and clinical profiles. Its major commercially available products include Gvoke for severe hypoglycemia, Keveyis for primary periodic paralysis, and Recorlev for Cushing's syndrome. Xeris also has a pipeline of development programs, including XP-8121 for hypothyroidism.

Xeris Biopharma Holdings, Inc. is headquartered in Chicago, Illinois, United States. The company operates internationally through subsidiaries located in Australia, the US, Ireland, and Sweden.

Xeris Biopharma Holdings, Inc.'s brand reputation over the past year appears to be mixed but generally leaning positive, particularly among analysts. While Weiss Ratings assigned a "Sell (D-)" rating to the stock, Zacks Research and Wall Street Zen recently upgraded their ratings to a "Strong Buy." Other firms like HC Wainwright and Leerink Partners have issued "Buy" and "Outperform" ratings, respectively. The company currently holds an average rating of "Moderate Buy" among analysts. Events that have positively affected Xeris Biopharma's reputation include its strong revenue growth and its innovative product pipeline.

Xeris Biopharma Holdings, Inc. has a diverse ownership structure, with institutional investors holding a significant portion of its shares. As of April 2025, 48.73% of Xeris Biopharma Holdings, Inc. shares were held by institutional owners. The general ownership breakdown includes approximately 56.7% by institutions, 4.48% by individual insiders, and 38.8% by the general public. Major institutional owners include BlackRock, Inc., Vanguard Group Inc., D. E. Shaw & Co., Inc., State Street Corp, Geode Capital Management, Llc, Morgan Stanley, and Millennium Management Llc.